JPAD-Journal of Prevention of Alzheimers Disease

Papers
(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats607
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217356
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France120
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice95
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort87
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data83
Herpes zoster and dementia : more evidences for a causal link73
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease63
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease63
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use56
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease51
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.45
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations41
Gene and genetic therapies in Alzheimer’s disease and other dementias39
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia33
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings32
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation31
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment28
Informal care for people with dementia in Europe28
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care28
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system27
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration26
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities26
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease25
0.059365034103394